Buy DSIP Delta-Sleep-Inducing Peptide – Peptide Partners

Product Overview & Specifications

DSIP, also known as delta-sleep-inducing peptide, is a research peptide supplied by Peptide Partners for in-vitro testing, laboratory experimentation, peptide-transport studies, neuroendocrine research, and preclinical investigation.

Published research has examined DSIP in cultured pituitary tissue, blood–brain-barrier permeability models, and human pheochromocytoma-cell systems. Research topics include pituitary-cell differentiation, transendothelial peptide flux, peptide stability, intracellular localization, and DSIP-like immunoreactive material.

These studies describe experimental cellular and tissue models and do not establish human safety, clinical efficacy, sleep-related treatment effects, or suitability for administration. Researchers should review the applicable batch documentation and certificate of analysis before beginning any experiment.

Product Specifications

The stated 99.81% purity is based on multi-vial testing. Researchers should review the batch-specific certificate of analysis before beginning any experiment.

Primary Research Studies & Findings

Induction of Pituitary Cell Type Differentiation by Delta Sleep-Inducing Peptide

Authors: A. G. Héritier, O. Stettler, and P. M. Dubois

Publication: Neuroendocrinology, 1994;59(5):477–482

DOI: 10.1159/000126694

Reference: PubMed 8022523

This in-vitro study examined the effects of DSIP on pituitary-cell differentiation. Pituitary primordia from 11-day-old rat fetuses were cultured in synthetic medium containing different DSIP concentrations. The researchers used immunocytochemical methods to quantify the expression of several pituitary-cell phenotypes.

DSIP exposure during the first day of culture was associated with dose-dependent differentiation of luteinizing-hormone and thyroid-stimulating-hormone cell types. The study also reported an effect on lactotrope differentiation, although the authors noted that this response might not have been direct. No effect was observed on somatotrope or corticotrope differentiation under the tested conditions.

Plain-English Research Summary

This laboratory study examined how DSIP influenced developing rat pituitary tissue. The researchers observed changes in specific pituitary-cell types, including cells associated with LH and TSH production. The findings describe an embryonic rat-tissue model and do not demonstrate a comparable effect in humans.

In-Vitro Characterization of Blood–Brain-Barrier Permeability to Delta Sleep-Inducing Peptide

Authors: S. Raeissi and K. L. Audus

Publication: Journal of Pharmacy and Pharmacology, 1989;41(12):848–852

DOI: 10.1111/j.2042-7158.1989.tb06385.x

Reference: PubMed 2576448

This study used an in-vitro blood–brain-barrier model consisting of cultured brain-microvessel endothelial-cell monolayers. DSIP movement across the cell layer was measured using a side-by-side diffusion apparatus and high-performance liquid chromatography with ultraviolet detection.

The reported transendothelial flux increased with DSIP concentration and was linear over time under the test conditions. The measured permeability was comparable to that of certain water-soluble substances with limited blood–brain-barrier penetration. DSIP transport was bidirectional, was not altered by reduced temperature or metabolic inhibitors, and showed limited degradation during the diffusion experiments.

Plain-English Research Summary

This study examined DSIP movement across a laboratory model of the blood–brain barrier. The researchers observed concentration-dependent transport and limited degradation during the test period. These findings characterize peptide permeability in an experimental cell model and do not establish distribution, activity, or safety in humans.

Human Pheochromocytoma Cells Studied in Culture Contain Large Amounts of DSIP-Like Material

Authors: Ola Nilsson, Bo Wängberg, Anneli Wigander, Kerstin Lundmark, Annica Dahlström, Håkan Ahlman, Anders Bjartell, and Rolf Ekman

Publication source: Peptides, 1991

Reference: View publication

This study investigated DSIP-like immunoreactive material in nine human pheochromocytoma tumors and in cultured cells derived from these tumors. The researchers used immunocytochemistry, immunofluorescence, electron microscopy, and high-performance liquid chromatography to examine the location and release of DSIP-like material.

Variable proportions of cells in the primary tumors showed cytoplasmic labeling with DSIP antibodies. Cultured tumor cells displayed concentrated labeling in cell bodies, while immunogold electron microscopy localized DSIP-like material to dense-core secretory granules. Several HPLC fractions from conditioned culture media indicated release of DSIP-like material from cultured cells.

The researchers also observed differences among tumor samples in the HPLC profiles of DSIP-like material. These variations may reflect differences in peptide processing, secretion, or turnover between the cell preparations.

Plain-English Research Summary

This study looked for DSIP-like material in human tumor tissue and cultured tumor cells. The researchers found immunoreactive material stored in cellular secretory granules and detected related material in the surrounding culture medium. The findings concern tumor-cell biology and do not establish the identity, function, or therapeutic significance of the supplied DSIP product.

Standard Research Disclaimer

Research Use Only. Not for use in diagnostic tests.

This product is solely intended for research purposes as a chemical compound. It is designated exclusively for in-vitro testing and laboratory experimentation. All information provided about this product is educational and should be evaluated by appropriately qualified research personnel.

By law, bodily introduction of this product into humans or animals is strictly prohibited. This compound must not be used, administered, or represented as a drug, food, dietary supplement, cosmetic, diagnostic material, sleep aid, or medical treatment. It is not intended to diagnose, treat, cure, or prevent any disease. It should be handled only by licensed and qualified professionals in an appropriately equipped laboratory and in accordance with applicable laws, institutional procedures, and relevant safety requirements.